CF PharmTech Secures RMB 440 Million Series D Financing to Advance Innovation and Globalization of Inhaled Therapeutics

VCBeat (WeChat ID: vcbeat) has recently learned that CF PharmTech, Inc. (hereinafter referred to as “CF PharmTech”) has successfully completed its Series D financing round of RMB 440 million. The round was led by the Advanced Manufacturing Industry Investment Fund managed by SDIC Fund Management Co., Ltd. (hereinafter referred to as “SDIC Innovation”), with participation from both new and existing investors including CCB International, Qianhai Yuanming, Longmen Investment, and Hengyu Tianze. The successful completion of this financing round demonstrates that key institutional investors in China’s healthcare industry are actively positioning themselves to support outstanding enterprises pursuing international competitiveness in high-end pharmaceutical formulations.

CF PharmTech, Inc. is a pharmaceutical company founded by a team of scientists and entrepreneurs who studied in the United States, dedicated to providing high-quality respiratory medicines globally. Since its inception, the company has focused on the research and development of inhaled formulations, a segment of the domestic market that has long relied on multinational corporations. Currently, CF PharmTech has successfully established an advanced R&D platform and production facilities for inhaled formulations. The company has more than 15 investigational projects under review for both domestic and international markets, covering key therapeutic areas for respiratory diseases. Several of these products have already entered clinical trials, with several more expected to complete their regulatory submission plans this year. Dr. Li Li, one of the company’s co-founders, is a talent introduced under China’s national recruitment program. He brings over 20 years of extensive experience in R&D and corporate management within the U.S. inhaled formulation industry and has successfully contributed to the development of multiple inhaled formulation products approved for marketing in the United States.

Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and rhinitis have become prevalent global health conditions. In China, the potential patient population for asthma and COPD exceeds 100 million, with COPD being the leading cause of death in many regions across the country. Although inhaled formulations are the gold-standard therapy for respiratory diseases, multinational corporations have long dominated approximately 90% of the domestic market. This monopoly has kept the cost of long-term chronic disease management prohibitively high, preventing a large number of patients from receiving adequate pharmacological treatment. The development of such dosage forms represents a high-barrier, technically complex segment of advanced drug delivery systems, with only a limited number of companies worldwide dedicated to their innovation. CF PharmTech has been actively cultivating this field for many years, and its pipeline products are poised for imminent launch in both domestic and international markets.

Mr. Lu Hai, Executive Director of SDIC Innovation, stated, “Inhaled formulations represent a niche segment within the high-end pharmaceutical preparation industry characterized by significant technical barriers. As a rising star in the field of inhaled formulations, CF PharmTech has gathered numerous elites from China’s inhaled formulation technology sector. We are full of expectations for the future development of CF PharmTech.”

Tian Yuan, Founder of Qianhai Yuanming Capital (a participant in this round of investment), Founder and Chairman of the Yabuli China Entrepreneurs Forum, Founder and Chairman of the China-U.S. Business Leaders Roundtable, and Vice Chairman of the Pharmaceutical Innovation Investment Professional Committee under the China Association for Pharmaceutical Innovation, stated, “In an era marked by population aging, respiratory diseases will pose a significant challenge. CF PharmTech is committed to addressing unmet medical needs and leading industry innovation, making its future development highly promising.”

Dr. Liang Wenqing, Co-founder, Chairman and CEO of CF PharmTech, stated: “This financing round marks a milestone in the development of CF PharmTech and serves as an affirmation of our team’s eight-year entrepreneurial journey. The introduction of leading domestic industrial investors, such as Sdic Fund Management Co., Ltd., will accelerate the market launch of our products currently under development, ensuring that high-quality major respiratory medications benefit patients in China at an earlier date. This financing will help us establish world-class R&D and manufacturing facilities for inhalation preparations and attract top-tier talent in this field from both home and abroad to join our team.”

About CF PharmTech

CF PharmTech, Inc. was founded in 2008 as a pharmaceutical enterprise supported by the Wuxi “530 Plan,” dedicated to the domestic and international development of advanced drug formulations. The company’s R&D headquarters is located in the Jiangnan University Science Park in Wuxi, while its production base is situated in the Su-Xiang Cooperative Development Zone in Suzhou. Since its inception, the company has received support from domestic industrial funds and renowned investment institutions, securing investments from Shuanglu Pharmaceutical, Sihong Investment, Galaxy Investment, Kaifeng Venture Capital, Jinfeng Lingheng, Sino-Singapore Venture Capital, Wuhu Ruiye, and Jinpu Health, among others. CF PharmTech focuses on the technological development and product R&D of aerosols, dry powder inhalers, nasal sprays, and nebulizer solutions, having established R&D platforms and production facilities for these dosage forms. The company’s founding mission is to provide Chinese patients with comprehensive access to high-quality inhaled medications, while actively participating in high-level competition in the European and American markets for inhaled formulations.

 The factory located in the Suzhou Xiangcheng Economic Development Zone has been put into operation.

About SDIC Innovation

SDIC Innovation was established in July 2009 as a professional private equity management firm operating independently in accordance with market-oriented principles. With funds under direct or indirect management exceeding RMB 50 billion, its managed capital encompasses state-owned capital, private capital, social security funds, and insurance funds, making it one of the largest professional private equity management firms in China.